| 自拟行气化瘀方治疗肝气郁结型代偿期乙肝肝硬化的临床研究 |
| Clinical research of self -propyration of qi and stasis treatment of liver qi stagnation period compensation period B hardening |
| DOI： |
| 中文关键词: 行气化瘀方 肝气郁结型 代偿期乙肝肝硬化 抗肝纤维化 临床研究。 |
| 英文关键词: Qi and stasis recipes liver qi stagnation type liver cirrhosis anti -liver fibrosis clinical research. |
| 基金项目:河北省邢台市科技局社会发展领域专项 项目编号2022ZC136，自拟行气化瘀方治疗肝气郁结型代偿期乙肝肝硬化的临床研究 |
|
| 摘要点击次数: |
| 全文下载次数: |
| 中文摘要: |
| 目的：观察自拟行气化瘀方治疗肝气郁结型乙肝代偿期肝硬化的效果。方法：将100例入组患者随机平均分为两组；对照组患者给予常规内科护肝、抗病毒治疗,观察组在对照组的基础上联合中药行气化瘀方,均治疗3周,观察两组中医症候评分,血清肝纤维化指标：血清透明质酸(HA)、血清Ⅳ型胶原蛋白(hPCⅣ)、血清层粘连蛋白(LN)、血清三型前胶原N端肽(PN-P)及肝脏瞬时弹性硬度值(LSM值)的变化。结果：观察组中医症候评分总有效率高于对照组(P＜0.05)；观察组患者治疗后HA、hPCⅣ、LN、PN-P指标较治疗前均下降,且观察组hPCⅣ、PN-P水平较对照组明显下降(P＜0.05)；治疗后观察组患者LSM水平低于对照组(P＜0.05)。 结论：自拟行气化瘀方治疗肝气郁结型代偿期乙肝肝硬化有较好的临床疗效,可改善患者的肝纤维化水平,有效控制乙肝肝硬化进程。 |
| 英文摘要: |
| Objective: Observe the clinical efficacy of hepatitis B hardening during the treatment of liver qi and stagnation. Methods: Patients with liver stagnation during liver qi stagnation periods were randomly divided into 50 cases of observation group and control group; patients in the control group were treated with conventional internal internal treatment of liver care and antiviral treatment. Qiqi and stasis recipes, both treated for 3 weeks, observed two groups of traditional Chinese medicine syndrome scores, serum liver fibrosis indicators: serum hyaluronic acid (HA), serum IV collagen (hPCⅣ), serum layer adhesion (LN), serum serum Type three-end collagen N-end peptide (PN-P) and liver instantaneous elastic hardness (LSM values). Results: The total effective efficiency of the Chinese medicine syndrome of the observation group was higher than the control group (P <0.05); the level of the observation group patients HA, hPCIV, LN, and PN-P were reduced compared to before treatment (P <0.05), and the observation group treatment The level of HPC IV and PN-P was significantly lower than the control group (P <0.05); the LSM value of the observation group after treatment was significantly lower than that of the control group (P <0.05). Conclusion: It is a good clinical efficacy for the treatment of liver qi and stasis to treat liver qi stagnation. Hepatitis B sclerosis can improve the level of liver fibrosis of patients and effectively control the process of hepatitis B sclerosis. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |